Large Cap - Spark Newswire

1 minute read

The European Commission Has Approved Bristol Myers Squibb’s Reblozyl (Luspatercept) For Anemia Associated With Non-transfusion-dependent Beta-thalassemia

Today, 8:20 AM

The EC approval of Reblozyl was based on results from the Phase 2 BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia. Patients were

BMY

2 minute read

Biden Admin’s Upcoming Cybersecurity Strategy Can Potentially Put Businesses, Software Provides On Collision Course

By Vandana Singh

Today, 8:20 AM

The Biden administration is poised to release a new national cybersecurity strategy that aims to make software companies liable for security hacks rather than the companies facing the hack.

AMZN

2 minute read

Silvergate Capital Plagued By ‘Regulatory And Liquidity Challenges,’ JPMorgan Analyst Says

By AJ Fabino

Today, 8:20 AM

Shares of cryptocurrency-focused Silvergate Capital Corp (NYSE: SI) fell off of a cliff Thursday, plummeting 45% on its warning of a delay in its annual report and concerns over its

1 minute read

FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s

By Vandana Singh

Today, 8:20 AM

The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…

GSK

1 minute read

AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says

By Vandana Singh

Today, 8:20 AM

Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…

ABBV

2 minute read

Housing Market Correction: Rates Up, Lack Of Buyers, Cracks Forming In Home Improvement

By AJ Fabino

Today, 8:20 AM

The housing market, still in its relentless rough patch as mortgage rates continue to climb higher, is deterring buyers from making a move.

JPM

1 minute read

After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung Cancer Patients

By Vandana Singh

Today, 8:20 AM

Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual primary endpoints, event-free survival…

MRK

1 minute read

Johnson & Johnson-Backed Antiviral Candidate Effectively Prevents Influenza Infection

By Vandana Singh

Today, 8:20 AM

Cidara Therapeutics Inc (NASDAQ: CDTX) announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain.

CDTX

1 minute read

FDA AdComm Gives Thumbs Up To Pfizer’s RSV Vaccine Candidate For Elderly People

By Vandana Singh

Today, 8:20 AM

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc’s (NYSE:PFE) available data is adequate to…

PFE

1 minute read

FDA Approves Regeneron-Sanofi’s Sarilumab As First Biologic For Stiffness, Pain In Muscles

By Vandana Singh

Today, 8:20 AM

The FDA approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval…

REGN